The Effects of Ketamine on the Expression of Hippocampal ��-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and Novel Object Placement Performance in a Wistar-Kyoto Model Depression
Presentation Type
Poster
Faculty Advisor
Alan Pehrson
Access Type
Open Access
Start Date
26-4-2023 12:30 PM
End Date
26-4-2023 1:30 PM
Description
Major Depressive Disorder (MDD) is a widespread mood disorder having severe consequences on one's life due to its cognitive and emotional impacts. Consequently, Major Depressive Disorder (MDD) is a leading cause of disability worldwide. Unfortunately, the existing treatments for MDD are connected with numerous undesired side effects and restrictions, leading many individuals not to respond appropriately to these therapies. Furthermore, the treatments available do not target symptoms of cognitive dysfunction caused by MDD. Recent studies show that Ketamine holds promise as a new treatment option for MDD. Studies have revealed its rapid and long-lasting antidepressant effects on serotonin and AMPA receptor systems. In this research, the influence of Ketamine on a hippocampus-dependent task, Novel Placement Object, will be investigated in an animal model reflecting depression symptoms using Wistar-Kyoto (WKY) rats. These animals display physiological and behavioral characteristics similar to those observed with Major Depressive Disorder(MDD). Moreover, another genetically similar group of Wistar-Hannover (Wistar-HAN) rats have been included as control subjects since they do not demonstrate sensitivity toward stress. As the primary hypothesis, we suggest that Ketamine treatment will reduce cognitive impairments in WKY rats compared to Wistar-HAN rats. Furthermore, our exploratory hypothesis suggests that Ketamine therapy may also amplify AMPA receptor expression within the hippocampus, which could be integral in its antidepressant qualities. The results of this investigation could contribute to our knowledge about Ketamine's antidepressant characteristics, laying the foundation for novel treatments that combat MDD-related cognitive issues.
The Effects of Ketamine on the Expression of Hippocampal ��-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and Novel Object Placement Performance in a Wistar-Kyoto Model Depression
Major Depressive Disorder (MDD) is a widespread mood disorder having severe consequences on one's life due to its cognitive and emotional impacts. Consequently, Major Depressive Disorder (MDD) is a leading cause of disability worldwide. Unfortunately, the existing treatments for MDD are connected with numerous undesired side effects and restrictions, leading many individuals not to respond appropriately to these therapies. Furthermore, the treatments available do not target symptoms of cognitive dysfunction caused by MDD. Recent studies show that Ketamine holds promise as a new treatment option for MDD. Studies have revealed its rapid and long-lasting antidepressant effects on serotonin and AMPA receptor systems. In this research, the influence of Ketamine on a hippocampus-dependent task, Novel Placement Object, will be investigated in an animal model reflecting depression symptoms using Wistar-Kyoto (WKY) rats. These animals display physiological and behavioral characteristics similar to those observed with Major Depressive Disorder(MDD). Moreover, another genetically similar group of Wistar-Hannover (Wistar-HAN) rats have been included as control subjects since they do not demonstrate sensitivity toward stress. As the primary hypothesis, we suggest that Ketamine treatment will reduce cognitive impairments in WKY rats compared to Wistar-HAN rats. Furthermore, our exploratory hypothesis suggests that Ketamine therapy may also amplify AMPA receptor expression within the hippocampus, which could be integral in its antidepressant qualities. The results of this investigation could contribute to our knowledge about Ketamine's antidepressant characteristics, laying the foundation for novel treatments that combat MDD-related cognitive issues.